Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Wendys Co (WEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Wendys Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Wendys Co trades at $7.44 (market cap $1.48B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 3× Wendys Co's market cap, and Wendys Co pays a 7.2% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WEN | |
|---|---|---|
Market Cap | $4.49B | $1.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $11.33 |
52-Week Low | $20.06 | $6.17 |
Enterprise Value | $3.69B | $5.30B |
Dividend Yield | — | 7.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Wendy's (WEN) trades at $7.78, down 9.53% today but up significantly from recent lows amid retail-driven momentum. The stock shows strong valuation metrics with P/E of 10.26 and P/S of 0.69, while recent earnings have consistently beaten expectations. Technical indicators suggest a bullish trend with key support at $7 and resistance at $8-9 levels. Recent news highlights digital sales growth and China expansion plans as potential catalysts.
The outlook remains mixed with fundamental challenges including declining net income margins (6.77% in 2025) and negative cash flow trends offset by attractive valuation and dividend yield. Key risks include weak U.S. traffic and cost inflation, while opportunities lie in international expansion and digital initiatives. Analyst consensus leans cautious with 65% hold ratings despite recent momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
